

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A compound comprising a tumor targeting unit, wherein:
the tumor targeting unit comprises ~~comprising a peptide, or a pharmaceutically or~~
physiologically acceptable salt thereof; ~~sequence;~~

the peptide consists of not more than seven amino acids;

the peptide has the sequence Cy-Rr_n-Dd-Ee-Ff-Rr_m-Cyy;

~~or a pharmaceutically or physiologically acceptable salt thereof, wherein,~~

Dd-Ee-Ff is Aa-Bb-Cc or Cc-Bb-Aa₃; ~~wherein~~

Aa, is isoleucine, leucine or *tert*-leucine, or a structural or functional analogue thereof₃;

Bb is arginine, homoarginine or canavanine, or a structural or functional analogue thereof;

Cc is serine or homoserine, or a structural or functional analogue thereof;

Rr are each, independently, any amino acid residue or a structural or functional analogue thereof;

n and m are, independently, 0, 1, or 2, and the sum of n and m does not exceed two; and;

~~Cy and Cyy are entities capable of forming~~ the peptide is a cyclic structure peptide.

2. (Canceled).

3. (Withdrawn-Currently Amended) The ~~tumor-targeting-unit~~compound according to ~~claim 2~~claim 1, wherein the cyclic ~~structure-peptide~~ is formed through an amide, lactam or disulphide bond.

4. (Withdrawn-Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 3, wherein one of Cy and Cyy is aspartic acid, glutamic acid or a structural or a functional analogue thereof, and the other is lysine, ornithine or a structural or functional analogue thereof.

5. (Withdrawn-Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 3, wherein Cy and Cyy are cysteine or a structural or functional analogue thereof.

6. (Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 1, wherein Rr are any amino acid residues, except histidine or lysine.

7. (Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 6, wherein Rr is selected from the group consisting of glycine, arginine and structural or functional analogues thereof.

8. (Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 5, wherein the peptide is selected from the group consisting of CLRSC (SEQ ID ~~NO~~NO: 1); and CSRLC (SEQ ID ~~NO~~NO: 2).

9. (Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 4, wherein the peptide is selected from the group consisting of DLRSK (SEQ ID ~~NO: NO:~~ 3), DLRSGRK (SEQ ID ~~NO: NO:~~ 4), DRGLRSK (SEQ ID ~~NO: NO:~~ 5), OLRSE (SEQ ID ~~NO: NO:~~ 6) and KLRSD (SEQ ID ~~NO: NO:~~ 7).

10. (Withdrawn-Currently Amended) The ~~tumor-targeting-unit~~compound according to claim 1, wherein the unit-compound is derivatized, activated, protected, resin bound or other support bound.

11. (Withdrawn-Currently Amended) A ~~tumor-targeting-agent~~compound according to claim 1, wherein the compound further comprises ~~comprising~~ at least one effector~~targeting~~ unit ~~according to claim 1,~~ directly or indirectly coupled to at least one ~~effector-tumor~~ targeting unit.

12. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 11, wherein the effector unit is a directly or indirectly detectable agent or a therapeutic agent.

13. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 12, wherein the detectable agent comprises an affinity label, a fluorescent or luminescent label, a chelator, a metal complex, an enriched isotope, radioactive material or a paramagnetic substance.

14. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 13, wherein the detectable agent comprises a rare earth metal.

15. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 14, wherein the detectable agent comprises gadolinium.

16. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 12, wherein the therapeutic agent is selected from the group consisting of cytotoxic, cytostatic and radiation emitting substances.

17. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 16, wherein the therapeutic agent comprises doxorubicin, daunorubicin, methotrexate or boron.

18. (Withdrawn-Currently Amended) The ~~tumor-targeting-agent~~compound according to claim 11, further comprising an optional unit.

19. (Withdrawn-Currently Amended) A diagnostic or pharmaceutical composition comprising at least one ~~targeting-unit~~compound according to claim 1.

20. (Withdrawn-Currently Amended) A method for the preparation of a medicament for the treatment of cancer or cancer related diseases comprising using a ~~targeting~~unitcompound according to claim 1.

21. (Withdrawn) The method according to claim 20, wherein said cancer or cancer related disease is a solid tumor.

22. (Withdrawn) The method according to claim 21, wherein said solid tumor is selected from the group consisting of carcinoma, sarcoma, melanoma or metastases.

23. (Withdrawn) A method for treating cancer or cancer related diseases, comprising providing to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 19.

24. (Withdrawn) The method according to claim 23, wherein said cancer or cancer related disease is a solid tumor.

25. (Withdrawn) The method according to claim 24, wherein said solid tumor is selected from the group consisting of carcinoma, sarcoma, melanoma or metastases.

26. (Withdrawn-Currently Amended) A diagnostic or pharmaceutical composition comprising at least one ~~targeting agent~~compound according to claim 11.

27. (Withdrawn-Currently Amended) A method for the preparation of a medicament for the treatment of cancer or cancer related diseases comprising using a ~~targeting agent~~compound according to claim 11.

28. (Withdrawn) A method for treating cancer or cancer related diseases, comprising providing to a patient in need thereof a therapeutically effective amount of a pharmaceutical composition according to claim 26.